Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-inside arthroscopic treatment of Hepple III osteochondral lesion of the talus: Jintian'ge vs sodium hyaluronate
ChiCTR2200066571Phase 4Not yet recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of sildenafil and sodium hyaluronate in osteochondral lesion of the talus (OLT) and ankle instability (CAI) (2 arms), sponsored by Xuzhou Central Hospital. Primary endpoints: Visual Analogue Scale, American Orthopedic Foot and Ankle Society Scoring System Score and 3 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
sildenafilsodium hyaluronate
03
Conditions
osteochondral lesion of the talus (OLT)ankle instability (CAI)
Beyond the preview
Go deeper on ChiCTR2200066571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066571.